Benzinga  Jan 28  Comment 
Six companies are set to go public on Friday. Below are details on the most anticipated biotech deal of the week. The two best deals of the week are thought to be Spark Therapeutics Inc (NASDAQ: ONCE) and Shake Shack (NYSE: SHAK). Spark...
FierceBiotech  Jan 28  Comment 
FierceBiotech is co-hosting an invitation-only event (there's no charge) with One Nucleus at the Queen Mary Innovation Centre in London to discuss how the year ahead is shaping up in the British biotech financing scene.
FierceBiotech  Jan 28  Comment 
With the Cambridge/Boston biotech supercluster forming a kind of global crossroads for drug development, bankers are going the extra mile to get in on the act. Wells Fargo life sciences specialist Katherine Andersen is uprooting herself from Palo...
FierceBiotech  Jan 28  Comment 
Ascendis Pharma cleared $108 million and Zosano Pharma raised $50 million in the first biotech IPOs of 2015, stoking hopes that the industry's window onto Wall Street will stay open well into the new year.
Market Intelligence Center  Jan 28  Comment 
S&P Biotech SPDR (XBI) traded between $200.21 and $206.72 before closing at $204.67 Tuesday and presents some attractive trading opportunities today according to's patented algorithms. The computer program that picks...
Benzinga  Jan 27  Comment 
Four more biotechnology companies are set to go public this Thursday. Details for these IPOs are listed below. The details and times of IPOs are subject to change. Ascendis Pharma Ascendis Pharma A/S (NASDAQ: ASND) is a biotech company...
Benzinga  Jan 27  Comment 
On Tuesday, the White House announced that Obama’s 2016 budget will include a hefty investment in antibiotic-resistant bacteria. The President’s plan includes about $1.2 billion worth of funding for research to combat drug-resistant...
Forbes  Jan 27  Comment 
In trading on Tuesday, precious metals shares were relative leaders, up on the day by about 2.6%. Leading the group were shares of International Tower Hill Mines (THM), up about 7.3% and shares of Fortuna Silver Mines (FSM) up about 5.8% on the day.
GenEng News  Jan 27  Comment 
Protein manufacturers must deal with their own sort of assembly line reject: the misfolded protein. Manufacturers can avoid the problem of tangled, gummed up, and hence useless proteins by relying on relatively costly production technologies, or...
FiercePharma  Jan 27  Comment 
Pharmaceuticals and biotechnology per se are not officially on the agenda, but both industries could be affected by the semi-annual meeting of the Cross-strait Economic Cooperation Committee set for Jan. 29 in Taipei. Taiwan biotechs meet a week...


Related Articles


Biotechnology is the use of molecular biology and genetic engineering techniques to develop treatments for human diseases. Many leading companies from the industry originated in the late 70's from university research laboratories. In the 1980s after attracting venture investors and after listed in the US stock exchange,have then developed into a growing industry that uses research innovations to develop new agricultural products, biomedical tools, and human therapies such as monoclonal antibody for cancer. In 2006, 92% of employees in the biotechnology industry worked in companies that specialized in developing new drugs or medical devices and equipment, while 8% were employed in companies that specialized in agricultural products. [1] The large cap company in the group is Amgen, Genentech, Biogen-Idec, Genzyme. iShares Nasdaq Biotechnology (IBB) offers a low risk/reward investment vehicle for long term investors

Industry Information

Major Biotechnology Companies

ISTA Pharmaceuticals (ISTA)

Biotechnology Industry Trends & Forces

High Pipeline Risk for New Drugs

Dependence on Health Insurance/Medicare Coverage

Dependence on Governmental Regulations

High Volatility and Instability at Start-up

Litigation Risk

Market Share


  1. State Bioscience Initiatives 2008 Report, published by the Biotechnology Industry Organization

Top Ten/Twenty Best Selling Drugs 2009

M&A Biotechnology

Monoclonal Antibody Market 2009

Vaccine Market 2009

Global Monoclonal Antibodies Market Review 2008 (World Top Ten mAbs)

M&A Review: Pharmaceutical & Biotechnology Industry

Global Vaccine Market Review 2008 (World Top Ten Vaccines)

Ipilimumab (BMS) Review: A Cancer Breakthrough?

Denosumab (Prolia, Amgen) FDA Review & Approval

Companies in the Biotechnology Industry (193)

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki